Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adma Biologics 465 STATE ROUTE 17 RAMSEY NJ 07446 USA

www.admabiologics.com P: 201-478-5552 F: 201-478-5553

Description:

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 2,464,130
Enterprise Value, $K 2,543,370
Shares Outstanding, K 231,809
Annual Sales, $ 258,220 K
Annual Net Income, $ -28,240 K
Last Quarter Sales, $ 81,880 K
Last Quarter Net Income, $ 17,810 K
EBIT, $ 45,000 K
EBITDA, $ 55,780 K
60-Month Beta 0.48
% of Insider Shareholders 3.70%
% of Institutional Shareholders 75.68%
Float, K 223,232
% Float 96.30%
Short Volume Ratio 0.53

Growth:

1-Year Return 173.26%
3-Year Return 518.02%
5-Year Return 188.86%
5-Year Revenue Growth 1,419.84%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.08 on 05/09/24
Next Earnings Date N/A
Earnings Per Share ttm 0.11
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year 366.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ADMA Ratios

Ratio
Price/Earnings ttm 98.00
Price/Earnings forward 30.80
Price/Earnings to Growth N/A
Return-on-Equity % 17.24%
Return-on-Assets % 7.38%
Profit Margin % -10.94%
Debt/Equity 0.85
Price/Sales 9.68
Price/Cash Flow 212.13
Price/Book 16.25
Book Value/Share 0.66
Interest Coverage -0.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar